AstraZeneca beats Q3 estimates on oncology strength (AZN:NASDAQ)
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS ...
Tuesday, February 3, 2026
Tag: Oncology
Guardant Health raises 2025 revenue outlook to $970M with Shield partnerships and strong oncology growth (NASDAQ:GH)
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking ...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.